臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

???ui.leftmenu.abouttair???
	???ui.leftmenu.explanation???

???ui.leftmenu.bartitle???
	Repositories
	Author
	Title
	Date
	???ui.leftmenu.statisticschart???
	???ui.leftmenu.realtimefacts???
	???ui.leftmenu.trend???

???index.news???
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

???ui.leftmenu.copyrighttitle???
	???ui.leftmenu.copyrightpublisher???
	???ui.leftmenu.copyrightconference???

???ui.leftmenu.link???
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"soo r a"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1???	???jsp.browse.items-by-author.order2???

Showing items 1-25 of 56 (3 Page(s) Totally)
1 2 3 > >>
View [10|25|50] records per page

Institution	Date	Title	Author
臺大學術典藏	2022-09-15T01:09:04Z	Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial	Shaw A.T.; Solomon B.J.; Chiari R.; Riely G.J.; Besse B.; Soo R.A.; Kao S.; Chia-Chi Lin; Bauer T.M.; Clancy J.S.; Thurm H.; Martini J.-F.; Peltz G.; Abbattista A.; Li S.; Ou S.-H.I.
臺大學術典藏	2022-09-15T01:08:59Z	Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC	Tan W.L.; Chua K.L.M.; Chia-Chi Lin; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; Yang J.C.; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F.
臺大學術典藏	2022-09-15T01:08:57Z	Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer	Peters S.; Shaw A.T.; Besse B.; Felip E.; Solomon B.J.; Soo R.A.; Bearz A.; Gadgeel S.M.; Chia-Chi Lin; Kao S.; Seto T.; Masters E.T.; Abbattista A.; Clancy J.S.; Thurm H.; Reisman A.; Peltz G.; Ross Camidge D.
臺大學術典藏	2022-09-15T01:08:53Z	An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC	Zhu V.W.; Lin Y.-T.; Kim D.-W.; Loong H.H.; Nagasaka M.; To H.; Ang Y.L.-E.; Ock C.-Y.; Tchekmedyian N.; Ou S.-H.I.; Syn N.L.; Reungwetwattana T.; Chia-Chi Lin; Soo R.A.
臺大學術典藏	2022-09-15T01:08:50Z	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC	Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Chia-Chi Lin; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H.
臺大學術典藏	2022-08-10T02:37:43Z	Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC	Tan W.L.; Chua K.L.M.; Lin C.-C.; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; CHIH-HSIN YANG; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F.
臺大學術典藏	2022-08-10T02:37:42Z	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC	Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; CHIH-HSIN YANG
臺大學術典藏	2022-08-10T02:37:41Z	Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial	CHIH-HSIN YANG; Mok T.S.K.; Lu S.; Nakagawa K.; Yamamoto N.; Shi Y.-K.; Zhang L.; Soo R.A.; Morita S.; Tamura T.
臺大學術典藏	2022-06-27T06:59:38Z	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC	Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; CHONG-JEN YU; Soo R.A.; Yang J.C.-H.
臺大學術典藏	2022-02-21T03:52:37Z	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer	Soh S.X.; Siddiqui F.J.; Allen J.C.; Kim G.W.; Lee J.C.; Yatabe Y.; Soda M.; Mano H.; Soo R.A.; Chin T.-M.; Ebi H.; Yano S.; Matsuo K.; Niu X.; Lu S.; Isobe K.; JIH-HSIANG LEE; Yang J.C.; Zhao M.; Zhou C.; Lee J.-K.; Lee S.-H.; Lee J.Y.; Ahn M.-J.; Tan T.J.; Tan D.S.; Tan E.-H.; Ong S.T.; Lim W.-T.
臺大學術典藏	2022-02-21T03:52:30Z	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC	Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H.
臺大學術典藏	2021-11-03T05:24:55Z	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC	Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; CHONG-JEN YU; Soo R.A.; Yang J.C.-H.
臺大學術典藏	2021-11-03T02:33:02Z	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC	Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; JIN-YUAN SHIH; Yu C.-J.; Soo R.A.; Yang J.C.-H.
臺大學術典藏	2021-08-20T08:00:38Z	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC	BIN-CHI LIAO; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H.
臺大學術典藏	2021-07-13T06:04:35Z	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer	Soh S.X.; Siddiqui F.J.; Allen J.C.; Kim G.W.; Lee J.C.; Yatabe Y.; Soda M.; Mano H.; Soo R.A.; Chin T.-M.; Ebi H.; Yano S.; Matsuo K.; Niu X.; Lu S.; Isobe K.; LEE JIH-HSIANG; Yang J.C.; Zhao M.; Zhou C.; Lee J.-K.; Lee S.-H.; Lee J.Y.; Ahn M.-J.; Tan T.J.; Tan D.S.; Tan E.-H.; Ong S.T.; Lim W.-T.
臺大學術典藏	2021-04-23T05:56:31Z	Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC	Tan W.L.;Chua K.L.M.;Lin C.-C.;Lee V.H.F.;Tho L.M.;Chan A.W.;Ho G.F.;Reungwetwattana T.;Ychih-Hsin Yang;Kim D.-W.;Soo R.A.;Ahn Y.C.;Onishi H.;Ahn M.-J.;Mok T.S.K.;Tan D.S.W.;Yang F.; Tan W.L.; Chua K.L.M.; Lin C.-C.; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; YCHIH-HSIN YANG; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F.
臺大學術典藏	2021-04-23T05:56:27Z	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial	Wu Y.-L.;Cheng Y.;Zhou J.;Lu S.;Zhang Y.;Zhao J.;Kim D.-W.;Soo R.A.;Kim S.-W.;Pan H.;Chen Y.-M.;Chian C.-F.;Liu X.;Tan D.S.W.;Bruns R.;Straub J.;Johne A.;Scheele J.;Park K.;Chih-Hsin Yang;Liu Z.;Chen X.;Wang M.;Yu S.;Zhang H.;Fang J.;Li W.;Yang C.-H.;Chang G.-C.;Hsia T.-C.;Yang C.-T.;Wang C.-C.;Cho B.C.;Lee K.H.;Kim Y.-C.;An H.J.;Woo I.S.;Cho J.Y.;Shin S.W.;Lee J.-S.;Kim J.-H.;Yoo S.S.;Kato T.;Shinagawa N.;Tan S.W.D.;Ngo L.S.-M.;Ratnavelu K.;Ahmad A.R.;Liam C.K.;De Marinis F.;Tassone P.;Molla A.I.;Calles Blanco A.;Lazaro Quintela M.E.;Felip Font E.;Dingemans A.-M.;Bui L.; Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L.
臺大學術典藏	2021-04-23T05:56:26Z	Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Final analysis of the GioTag study	Hochmair M.J.;Morabito A.;Hao D.;Yang C.-T.;Soo R.A.;Chih-Hsin Yang;Gucalp R.;Halmos B.;M?Rten A.;Cufer T.; Hochmair M.J.; Morabito A.; Hao D.; Yang C.-T.; Soo R.A.; CHIH-HSIN YANG; Gucalp R.; Halmos B.; M?rten A.; Cufer T.
臺大學術典藏	2020-08-13T06:33:31Z	Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors	Yun M.R.; Yun M.R.;Lim S.M.;Kim S.-K.;Choi H.M.;Pyo K.-H.;Kim S.K.;Lee J.M.;Lee Y.W.;Choi J.W.;Kim H.R.;Hong M.H.;Haam K.;Huh N.;Kim J.-H.;Kim Y.S.;Shim H.S.;Soo R.A.;Jin-Yuan Shih;Chih-Hsin Yang J.;Kim M.;Cho B.C.; Cho B.C.; Kim M.; Chih-Hsin Yang J.; JIN-YUAN SHIH; Soo R.A.; Shim H.S.; Kim Y.S.; Kim J.-H.; Lim S.M.; Kim S.-K.; Choi H.M.; Pyo K.-H.; Kim S.K.; Lee J.M.; Lee Y.W.; Choi J.W.; Kim H.R.; Hong M.H.; Haam K.; Huh N.
臺大學術典藏	2020-08-13T06:33:31Z	Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors	Yun M.R.; Yun M.R.;Lim S.M.;Kim S.-K.;Choi H.M.;Pyo K.-H.;Kim S.K.;Lee J.M.;Lee Y.W.;Choi J.W.;Kim H.R.;Hong M.H.;Haam K.;Huh N.;Kim J.-H.;Kim Y.S.;Shim H.S.;Soo R.A.;Jin-Yuan Shih;Chih-Hsin Yang J.;Kim M.;Cho B.C.; Cho B.C.; Kim M.; Chih-Hsin Yang J.; JIN-YUAN SHIH; Soo R.A.; Shim H.S.; Kim Y.S.; Kim J.-H.; Lim S.M.; Kim S.-K.; Choi H.M.; Pyo K.-H.; Kim S.K.; Lee J.M.; Lee Y.W.; Choi J.W.; Kim H.R.; Hong M.H.; Haam K.; Huh N.
臺大學術典藏	2020-05-26T09:27:20Z	First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009	Soo R.A;Anderson B.O;Cho B.C;Chih-Hsin Yang;Liao M;Lim W.-T;Goldstraw P;Mok T.S.; Soo R.A; Anderson B.O; Cho B.C; CHIH-HSIN YANG; Liao M; Lim W.-T; Goldstraw P; Mok T.S.
臺大學術典藏	2020-05-26T09:27:20Z	First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009	Soo R.A;Anderson B.O;Cho B.C;Chih-Hsin Yang;Liao M;Lim W.-T;Goldstraw P;Mok T.S.; Soo R.A; Anderson B.O; Cho B.C; CHIH-HSIN YANG; Liao M; Lim W.-T; Goldstraw P; Mok T.S.
臺大學術典藏	2020-05-26T09:27:17Z	The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer	Cho B.C;Kim J.H;Soo R.A;Chih-Hsin Yang; Cho B.C; Kim J.H; Soo R.A; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:27:17Z	The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer	Cho B.C;Kim J.H;Soo R.A;Chih-Hsin Yang; Cho B.C; Kim J.H; Soo R.A; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:27:15Z	Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer	Hensing T; Lee C; Gupta N; Pradhan R; Qian J; Qin Q; Scappaticci F.A; Ricker J.L; Carlson D.M; Soo R.A.; Tan E.-H;Goss G.D;Salgia R;Besse B;Gandara D.R;Hanna N.H;Chih-Hsin Yang;Thertulien R;Wertheim M;Mazieres J;Hensing T;Lee C;Gupta N;Pradhan R;Qian J;Qin Q;Scappaticci F.A;Ricker J.L;Carlson D.M;Soo R.A.; Tan E.-H; Goss G.D; Salgia R; Besse B; Gandara D.R; Hanna N.H; CHIH-HSIN YANG; Thertulien R; Wertheim M; Mazieres J

Showing items 1-25 of 56 (3 Page(s) Totally)
1 2 3 > >>
View [10|25|50] records per page

	English \| 正體中文 \| 简体中文 \| 2818357
	???header.visitor??? : 28046374 ???header.onlineuser??? : 1349 ???header.sponsordeclaration???